The charts on this telehealth stock point to strong gains ahead, according to Katie Stockton

Hims & Hers Health (HIMS) is exhibiting a healthy cyclical uptrend, supported by positive long-term momentum and technical indicators suggesting continued short-term upside towards the $65-$66 range. This bullish technical outlook is reinforced by a strong fundamental view, with projected annual revenue growth of 134% to $3.5 billion by 2027 within a total addressable market exceeding $25 billion. Investors should note its high volatility, with an adjusted beta of approximately 2.09, and monitor the 50-day moving average near $51 as a key support level.

Analysis

Hims & Hers Health, Inc. (HIMS) is exhibiting a strong technical and fundamental profile. The stock is maintaining a healthy cyclical uptrend, trading above key long-term support levels including its weekly cloud and 200-day moving average. This bullish posture is reinforced by a fundamental outlook forecasting 134% annual revenue growth to $3.5 billion by 2027, tapping into a total addressable market exceeding $25 billion. Short-term indicators are also positive; a recent rally from the 50-day moving average has triggered bullish turns in the weekly stochastic oscillator and the MACD histogram, suggesting upside momentum could persist for several weeks toward the $65–$66 resistance zone. Furthermore, HIMS demonstrates significant relative strength, consistently outperforming the S&P 500 Index with its relative ratio trading above a rising 200-day moving average. However, the stock's high volatility, evidenced by an adjusted beta of approximately 2.09, presents a key risk factor, with the nearest major support at the 50-day MA near $51, representing a potential downside of over 12% from current levels.

Key Decisions for Investors

• Given the confluence of a healthy uptrend, positive short-term momentum signals, and strong fundamental growth forecasts, the current consolidation phase could represent a favorable accumulation opportunity for bullish investors.
• Investors must actively manage risk due to the stock's high volatility, indicated by its 2.09 adjusted beta, and should use the 50-day moving average near $51 as a critical support level to monitor for any potential trend reversal.
• The stock's sustained outperformance against the S&P 500, supported by positive signals in its relative strength ratio, makes it a candidate for overweight positioning in portfolios seeking alpha over the broad market.